Koethe, John R.
Lagathu, Claire
Lake, Jordan E.
Domingo, Pere
Calmy, Alexandra
Falutz, Julian
Brown, Todd T.
Capeau, Jacqueline
Article History
Accepted: 5 May 2020
First Online: 18 June 2020
Change Date: 2 July 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: J.R.K. has received research support from Gilead Sciences and served as a consultant to Gilead Sciences and Theratechnologies. J.E.L. receives research support from Gilead Sciences and has served as a consultant to Gilead Sciences and Merck Sharp & Dohme. P.D. has received educational grants from and served as a consultant to Gilead Sciences, Johnson & Johnson, Merck Sharp & Dohme, and ViiV Healthcare. A.C. received unrestricted educational grants (to the institution) from BMS, Gilead, Merck Sharp & Dohme and ViiV Healthcare. J.F. has served on speakers’ bureaus from Gilead Sciences, Merck Sharp & Dohme and ViiV Healthcare, and has served as a consultant to Theratechnologies up to 2015. T.T.B. has served as a consultant to Gilead Sciences, Merck, Theratechnologies and ViiV Healthcare. J.C. has received research support (to the institution) from Janssen, Merck Sharp & Dohme and ViiV Healthcare, and educational grants from BMS, Gilead Sciences, Janssen, Merck Sharp & Dohme and ViiV Healthcare. C.L. declares no competing interests.
Free to read: This content has been made available to all.